During the past decade, Universitätsmedizin Rostock conducted 79 clinical trials. In the 10-year time frame, 79 clinical trials started and 21 clinical trials were completed, i.e. on average, 26.6% percent of trials that started reached the finish line to date. In the past 5 years, 44 clinical trials started and 12 clinical trials were completed. i.e. 27.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitätsmedizin Rostock" #1 sponsor was "Janssen Research & Development, LLC" with 6 trials, followed by "German CLL Study Group" with 5 trials sponsored, "Valneva Austria GmbH" with 4 trials sponsored, "Biotronik SE & Co. KG" with 3 trials sponsored and "Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company" with 3 trials sponsored. Other sponsors include 93 different institutions and companies that sponsored additional 80 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitätsmedizin Rostock" #1 collaborator was "Roche Pharma AG" with 3 trials as a collaborator, "Amgen" with 2 trials as a collaborator, "Cancer Trials Ireland" with 2 trials as a collaborator, "Charite University, Berlin, Germany" with 2 trials as a collaborator and "Deutsche Kinderkrebsstiftung" with 2 trials as a collaborator. Other collaborators include 100 different institutions and companies that were collaborators in the rest 104 trials.

According to Clinical.Site data, the most researched conditions in "Universitätsmedizin Rostock" are "Atrial Fibrillation" (6 trials), "Coronary Artery Disease" (5 trials), "Heart Failure" (4 trials), "Aortic Valve Stenosis" (3 trials) and "Japanese Encephalitis" (3 trials). Many other conditions were trialed in "Universitätsmedizin Rostock" in a lesser frequency.

Most popular intervention types in "Universitätsmedizin Rostock" are "Drug" (63 trials), "Biological" (22 trials), "Device" (17 trials), "Other" (13 trials) and "Procedure" (9 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (20 trials), "Obinutuzumab" (5 trials), "Ibrutinib" (4 trials), "Venetoclax" (4 trials) and "Edoxaban" (3 trials). Other intervention names were less common.

The vast majority of trials in "Universitätsmedizin Rostock" are 117 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Universitätsmedizin Rostock". undefined are not yet recruiting, 28 are recruiting, 20 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 51 completed trials in Universitätsmedizin Rostock, undefined suspended trials, and 14 terminated clinical trials to date.

Out of the total trials that were conducted in Universitätsmedizin Rostock, 4 "Phase 1" clinical trials were conducted, 29 "Phase 2" clinical trials and 49 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 14 trials that are defined as “Not Applicable".